|ECR 2019 / C-1620|
|Usefulness of fusion MRI in ADC analysis after neoadjuvant chemotherapy in patients with breast cancer|
Breast volumes: 2 patients showed no response to chemotherapy. 38 patients showed a response to chemotherapy and were divided into three responders groups: complete responders, responders with reduction of tumor lesions >80% and responders with reduction of tumor lesions < 80%.
At 1.5 tesla scanner 28 patients were evaluated : 9 patients had complete regression of breast cancer, 7 patients had a volume reduction of breast lesion > 80% and 12 patients had a volume reduction of breast tumor <80% .
At 3Tesla scanner 10 patients were evaluated: 4 patients showed a complete regression of breast cancer , 3 patients had a volume reduction >80% and 3 patients had a volume reduction < 80%.
Using the non parametric test Wilcoxon test to analyze the volume reduction of breast lesions examined at 1.5 tesla and at 3 Tesla we obtained a statistically significant volume reduction( P value <0.0001) , even at 3tesla with a very small patients sample size (Fig 3 - Fig4 – Fig .5).
We analyzed ADC values by Wilcoxon test and we noticed that patients with complete response showed lower ADC values (mean=0,590 ± 0,16 x 10-3 mm2/s). Post NACT ADC values of responder patients >80% were significantly higher than pre- treatment values (mean=1,23±0,2 vs mean=0,880±0,28) (p=0,02); in patients with decrease of tumor volume< 80% there was no statistically significant difference between pre and post treatment ADC values ( mean= 0,85±0,15 vs mean=0,93±0,22) (p=0,778) (Fig. 6 )
The pre and post treatment ADC values obtained from the 3T sample using fusion technique, didn’t shown a statistically significant difference (p<0.625) , probably due to the small sample size, although ADC values tended to increase after NACT.( Fig.7- Fig.8)
Thematically related posters
ECR 2019 / C-0525
Influence of ROI placement: different ADC metrics on diagnostic accuracy of DWI in NME breast tumours
ECR 2019 / C-1117
Multiparametric MRI with dynamic contrast enhanced MRI and diffusion weighted imaging for the assessment of non-mass enhancing breast tumours